What is PneumoWave?
Founded in 2018, PneumoWave operates at the intersection of medical technology and data science. The company specializes in the real-time capture and analysis of physiological signals to preemptively identify respiratory distress. By shifting the clinical paradigm from reactive treatment to proactive intervention, PneumoWave aims to mitigate the severity of respiratory events before they necessitate emergency hospital admissions. Their core technology serves as a critical diagnostic layer, providing clinicians with actionable insights that facilitate timely medical responses and improved patient outcomes in high-risk populations.
How much funding has PneumoWave raised?
PneumoWave has raised a total of $9.1M across 1 funding round:
Series A
$9.1M
Series A (2023): $9.1M with participation from Scottish Enterprise, Scottish National Investment Bank, and Alba Equity
Key Investors in PneumoWave
Scottish Enterprise
A national economic development agency and non-departmental public body of the Scottish Government, focused on fostering innovation and economic growth.
Scottish National Investment Bank
A development investment bank providing long-term, patient capital to support sustainable economic growth, innovation, and technological advancement.
Alba Equity
An Aberdeen-based investment syndicate that provides capital and strategic mentorship to high-growth businesses with clear routes to market.
What's next for PneumoWave?
With the recent influx of capital, PneumoWave is poised to scale its operations and deepen its clinical validation efforts. The company's strategic roadmap focuses on integrating its monitoring solutions into broader healthcare ecosystems, thereby enhancing the standard of care for patients with chronic respiratory conditions. As the firm moves forward, the focus will likely shift toward regulatory milestones and commercial expansion, leveraging the support of its institutional backers to navigate the complexities of the medical device market. The company remains committed to its core objective of reducing mortality rates and hospital utilization through continuous, data-driven physiological surveillance.
See full PneumoWave company page
